Servier, Neurochlore Initiates Trial To Evaluate Bumetanide In Children With Autism Spectrum Disorder

French pharmaceutical organization Servier and biotechnology organization Neurochlore recently announced they are launching phase 3 studies to evaluate the use of Bumetanide in children with autism spectrum disorder (ASD). Bumetanide is classically used to treat fluid retention (edema) and high blood pressure.

The plan for the two six-month studies was recently approved by the Pediatric Committee of the European Medicines Agency, and will monitor the children having Bumetanide administered to them twice daily to evaluate its efficacy and safety in alleviating ASD symptoms. The evaluation will particularly focus on the children's performance with social communication and interaction, as . . .